{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Primary+Immune+Thrombocytopenia+%28ITP%29",
    "query": {
      "condition": "Primary Immune Thrombocytopenia (ITP)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 65,
    "total_pages": 7,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Primary+Immune+Thrombocytopenia+%28ITP%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-11T02:28:07.214Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06291415",
      "title": "The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Immune Thrombocytopenia",
        "Blood Platelet Disorder",
        "Hematologic Diseases",
        "Purpura, Thrombocytopenic",
        "Purpura",
        "Blood Coagulation Disorder",
        "Thrombotic Microangiopathies",
        "Hemorrhagic Disorders",
        "Autoimmune Diseases",
        "Immune System Diseases",
        "Hemorrhage",
        "Pathologic Processes",
        "Skin Manifestations",
        "Thrombocytopenia",
        "Purpura, Thrombocytopenic, Idiopathic",
        "Primary Immune Thrombocytopenia",
        "ITP - Immune Thrombocytopenia"
      ],
      "interventions": [
        {
          "name": "HMPL-523",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hutchmed",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2024-04-02",
      "completion_date": "2026-11",
      "has_results": false,
      "last_update_posted_date": "2025-09-16",
      "last_synced_at": "2026-06-11T02:28:07.214Z",
      "location_count": 10,
      "location_summary": "Irvine, California • Georgetown, Delaware • Bethesda, Maryland + 7 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Georgetown",
          "state": "Delaware"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Farmington",
          "state": "New Mexico"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06291415"
    },
    {
      "nct_id": "NCT04596995",
      "title": "A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Immune Thrombocytopenia"
      ],
      "interventions": [
        {
          "name": "Rozanolixizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UCB Biopharma SRL",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2021-01-06",
      "completion_date": "2022-12-21",
      "has_results": true,
      "last_update_posted_date": "2024-02-05",
      "last_synced_at": "2026-06-11T02:28:07.214Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04596995"
    },
    {
      "nct_id": "NCT04904276",
      "title": "Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "ITP",
        "Immune Thrombocytopenia"
      ],
      "interventions": [
        {
          "name": "Fostamatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rigel Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 16,
      "start_date": "2021-05-18",
      "completion_date": "2022-11-17",
      "has_results": false,
      "last_update_posted_date": "2024-03-15",
      "last_synced_at": "2026-06-11T02:28:07.214Z",
      "location_count": 14,
      "location_summary": "Tamarac, Florida • Springfield, Illinois • Kansas City, Kansas + 10 more",
      "locations": [
        {
          "city": "Tamarac",
          "state": "Florida"
        },
        {
          "city": "Springfield",
          "state": "Illinois"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04904276"
    },
    {
      "nct_id": "NCT01143038",
      "title": "Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Idiopathic Thrombocytopenic Purpura"
      ],
      "interventions": [
        {
          "name": "Romiplostim",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 75,
      "start_date": "2010-11-30",
      "completion_date": "2013-12-26",
      "has_results": true,
      "last_update_posted_date": "2022-09-21",
      "last_synced_at": "2026-06-11T02:28:07.214Z",
      "location_count": 8,
      "location_summary": "Anaheim, California • Orange, California • Boynton Beach, Florida + 5 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Boynton Beach",
          "state": "Florida"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Hickory",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01143038"
    },
    {
      "nct_id": "NCT00049725",
      "title": "Daclizumab to Treat Chronic Immune Thrombocytopenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Thrombocytopenia"
      ],
      "interventions": [
        {
          "name": "Daclizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institutes of Health Clinical Center (CC)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 24,
      "start_date": "2002-11",
      "completion_date": "2004-12",
      "has_results": false,
      "last_update_posted_date": "2008-03-04",
      "last_synced_at": "2026-06-11T02:28:07.214Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00049725"
    },
    {
      "nct_id": "NCT01054443",
      "title": "A Study to Investigate the Efficacy and Safety of Lusutrombopag (S-888711) Tablets Administered to Adults With Immune Thrombocytopenia (ITP)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Immune Thrombocytopenia (ITP)"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Lusutrombopag",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shionogi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2010-03-18",
      "completion_date": "2010-11-24",
      "has_results": true,
      "last_update_posted_date": "2021-03-18",
      "last_synced_at": "2026-06-11T02:28:07.214Z",
      "location_count": 19,
      "location_summary": "Anaheim, California • Los Angeles, California • Washington D.C., District of Columbia + 15 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Boynton Beach",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01054443"
    },
    {
      "nct_id": "NCT07007962",
      "title": "Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Immune Thrombocytopenia"
      ],
      "interventions": [
        {
          "name": "rilzabrutinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2025-10-24",
      "completion_date": "2028-12-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-27",
      "last_synced_at": "2026-06-11T02:28:07.214Z",
      "location_count": 9,
      "location_summary": "Clovis, California • New Orleans, Louisiana • Boston, Massachusetts + 5 more",
      "locations": [
        {
          "city": "Clovis",
          "state": "California"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07007962"
    },
    {
      "nct_id": "NCT03275740",
      "title": "A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy",
        "Primary Immune Thrombocytopenia",
        "Polyradiculoneuropathy, Chronic Inflammatory Demyelinating"
      ],
      "interventions": [
        {
          "name": "PF-06755347 intravenous healthy participant",
          "type": "DRUG"
        },
        {
          "name": "Placebo intravenous healthy participant",
          "type": "DRUG"
        },
        {
          "name": "PF-06755347 subcutaneous healthy participant",
          "type": "DRUG"
        },
        {
          "name": "Placebo subcutaneous healthy participant",
          "type": "DRUG"
        },
        {
          "name": "PF-06755347 subcutaneous ITP",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 58,
      "start_date": "2017-07-17",
      "completion_date": "2023-01-06",
      "has_results": true,
      "last_update_posted_date": "2024-07-05",
      "last_synced_at": "2026-06-11T02:28:07.214Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03275740"
    },
    {
      "nct_id": "NCT06721013",
      "title": "A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Immune Thrombocytopenia (ITP)"
      ],
      "interventions": [
        {
          "name": "Pirtobrutinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 58,
      "start_date": "2025-07-30",
      "completion_date": "2027-02",
      "has_results": false,
      "last_update_posted_date": "2026-05-12",
      "last_synced_at": "2026-06-11T02:28:07.214Z",
      "location_count": 11,
      "location_summary": "Los Angeles, California • Stanford, California • Washington D.C., District of Columbia + 8 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06721013"
    },
    {
      "nct_id": "NCT00359463",
      "title": "Study Of Eltrombopag in Healthy Subjects and Volunteers With Mild, Moderate or Severe Hepatic Impairment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Purpura, Thrombocytopaenic, Idiopathic"
      ],
      "interventions": [
        {
          "name": "eltrombopag",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 33,
      "start_date": "2006-04-18",
      "completion_date": "2007-03-07",
      "has_results": false,
      "last_update_posted_date": "2017-11-13",
      "last_synced_at": "2026-06-11T02:28:07.214Z",
      "location_count": 2,
      "location_summary": "Gainesville, Florida • Orlando, Florida",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00359463"
    }
  ]
}